UPDATE: Wedbush Reiterates Outperform Rating, Raises PT on Chelsea Therapeutics International on Successful Appeal

In a report published Wednesday, Wedbush reiterated its Outperform rating on Chelsea Therapeutics International (NASDAQ: CHTP ), and raised its price target from $5.00 to $7.00. Wedbush noted, “Chelsea's apparently successful appeal to the Office of New Drugs may reduce regulatory risk for Northera. Recall that Chelsea is developing Northera,